Median Technologies presents its iCRO offering at ESMO 2026 Congress in Madrid
In a press release published on October 21, 2026, Median Technologies announced its participation in the Congress of the European Society for Medical Oncology (ESMO), held from October 23 to 27, 2026 at IFEMA Madrid, Spain. The announcement falls under institutional communication: it concerns the company's presence at this key event for the international oncology community and does not involve any new strategic decisions.
The iCRO team presents its services at booth no. 1098
The offering presented in Madrid concerns Median Technologies' iCRO activity, dedicated to centralized imaging services and image analysis using artificial intelligence for clinical trials in oncology conducted by the biopharmaceutical industry. The iCRO team will welcome participants at booth no. 1098, located in Hall 10, from October 23 to 26, from 10 a.m. to 6:30 p.m., during technical exhibition hours.
According to the press release, it will present "the latest advances" in these services. The group, headquartered in Valbonne, also develops Eyonis, a suite of artificial intelligence-based medical device software designed for early detection and diagnosis of cancers.
Also present in the United States and China, the company is listed on Euronext Growth and is eligible for PEA-PME.
A session on RANO 2.0 and a poster dedicated to emphysema
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Median Technologies will organize an interactive session on its booth dedicated to lessons learned from the implementation of RANO 2.0, the updated framework for assessing therapeutic response in neuro-oncology, in the context of centralized image review. Entitled "RANO 2.0 in Central Imaging Review: Driving Success in Neuro-Oncology Trials", it will take place on October 25, from 12 p.m. to 12:30 p.m.
It will be moderated by Antoine Iannessi, VP Medical Affairs of the iCRO activity, and by Anne-Sophie Auroux, VP Operations of this same activity.
The company will also present an electronic poster (reference 2560eP) entitled "Prevalence of Emphysema in Patients with Non-Small Cell Lung Cancer (NSCLC)", focusing on the prevalence of emphysema in patients with non-small cell lung cancer.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 11,8 millions d'euros
Quarterly revenue: 11,8 millions d'euros
Guidance from the release
The Company expects continued growth of its profitable iCRO business, supported by record backlog levels and favorable commercial momentum, but primary focus remains execution of eyonis® LCS commercialization with inherent execution risk.
Risks mentioned
Risques de fluctuations de demande dans l'industrie biopharmaceutique.
Réglementations changeantes pouvant impacter la commercialization.
Concurrence accrue sur le marché des dispositifs médicaux.
Opportunities identified
Lancement commercial d'eyonis® LCS aux États-Unis.
Partenariat stratégique avec Tempus AI en cours.
Croissance continue de l'activité iCRO avec des niveaux de carnet de commandes record.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
